Home
University & Research Institutions

Sector: University & Research Institutions

Your guide to synthetic drug royalty dealmaking

Selling revenue streams is an increasingly important way of monetising pharma innovations

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

France Brevets’ public sector links hindered monetisation efforts, says CEO

As the sovereign patent fund closes down, CEO Didier Patry shares his thoughts with IAM readers on the organisation’s work over the past decade

Latest content

UK government blocks IP deal with Chinese company using radical new powers

Recently implemented legislation gives the British government the ability to intervene in IP transactions

22 July 2022

There are dangers in excluding the unvaccinated from jury service in US patent cases

Courts striking-out those who have not had covid-19 jabs may unintentionally be eliminating people from diverse demographics holding multiple world views

16 July 2022

Royalty Pharma spends $1.3 billion in latest drug revenue rights purchase

Royalty transactions are an increasingly attractive means of cashing in on life sciences innovation, and the returns can be significant

15 July 2022

Data monetisation gathers momentum in the healthcare sector

Life sciences innovators are increasingly paying for access to high-quality data

27 June 2022

French appeal court SPC decision is good news for biologics innovators

Following a string of adverse rulings against inventors, Paris Court of Appeal overturns patent office rejection of supplementary protection certificate on Article 3(a) grounds

20 June 2022

UCal further strengthens CRISPR position in Europe, but Cas9 licensing situation remains tricky

EPO Opposition Division upholds another key Doudna patent, but several gene-editing appeals are still in play

26 May 2022

Stealthy biotech buys up patent portfolios in string of recent deals

Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months

04 May 2022

Columbia University scores $185 million jury verdict on back of anti virus patents

NortonLifeLock has pledged to appeal the jury verdict, which could balloon to $550 million with enhanced damages for wilful infringement

03 May 2022

CRISPR FTO complexities not going anywhere in wake of Broad Institute victory, says IP chief on the CVC side

Following major US CRISPR decision, Michael Arciero, VP of IP at ERS Genomics, tells IAM that tricky patent landscapes are the new normal in biotech

04 April 2022

Five key takeaways from IPBC Europe

Returning from two action-packed days in London, IAM Deputy Editor Adam Houldsworth reflects on the surprising state of corporate UPC strategies, the rise of AI, FRAND fireworks and more

02 April 2022

Unlock unlimited access to all IAM content